Novavax News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

08.09.21	Novavax Initiates Phase 1/2 Clinical Trial of Combination Vaccine for COVID-19 and Seasonal Influenza (PR Newswire)
07.09.21	Novavax to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021 (PR Newswire)
31.08.21	CDC Considers Novavax COVID-19 Vaccine Trial Participants As Fully Vaccinated Two Weeks After Dosing (RTTNews)
30.08.21	Novavax Statement on CDC Guidance Update for COVID-19 Clinical Trial Participants (PR Newswire)
25.08.21	OCTAVE-DUO Study To Evaluate Novavax' Vaccine Candidate In Participants With Impaired Immune Systems (RTTNews)
25.08.21	Novavax to Participate in OCTAVE-DUO Study to Evaluate Third Dose of Vaccine in Participants with Impaired Immune Systems (PR Newswire)
16.08.21	Novavax Names Jim Kelly CFO; Appoints Nasir Egal As SVP, Quality Assurance (RTTNews)
16.08.21	Novavax Appoints Biopharmaceutical Veterans Jim Kelly as Chief Financial Officer and Nasir Egal, Ph.D., as Senior Vice President of Quality Assurance (PR Newswire)
07.08.21	Novavax gibt Daten zum COVID-19-Auffrischimpfung bekannt, die einen vierfachen Anstieg der neutralisierenden Antikörperspiegel im Vergleich zu den Spitzenwerten nach der Erstimpfung belegen (PR Newswire)
07.08.21	Novavax und Serum Institute of India kündigen Antrag auf Notfallzulassung des rekombinanten Nanopartikel-COVID-19-Impfstoffs von Novavax bei den Zulassungsbehörden in Indien, Indonesien und auf de... (PR Newswire)
06.08.21	MÄRKTE USA/Neue Rekorde nach starkem Arbeitsmarktbericht (Dow Jones)
06.08.21	MÄRKTE USA/Etwas fester nach starkem Arbeitsmarktbericht (Dow Jones)
06.08.21	MÄRKTE USA/Wall Street von guten Arbeitsmarktdaten kaum bewegt (Dow Jones)
06.08.21	MÄRKTE USA/Wall Street von guten Jobdaten kaum bewegt (Dow Jones)
05.08.21	Novavax Announces COVID-19 Vaccine Booster Data Demonstrating Four-Fold Increase in Neutralizing Antibody Levels Versus Peak Responses After Primary Vaccination (PR Newswire)
05.08.21	Novavax and Serum Institute of India Announce Submission to Regulatory Agencies in India, Indonesia, Philippines for Emergency Use Authorization of Novavax' Recombinant Nanoparticle COVID-19 Vaccine (PR Newswire)
05.08.21	EARNINGS SUMMARY: Details of Novavax Inc. Q2 Earnings Report (RTTNews)
05.08.21	Novavax Reports Second Quarter 2021 Financial Results and Operational Highlights (PR Newswire)
05.08.21	Novavax Announces COVID-19 Vaccine Booster Data Demonstrating Four-Fold Increase in Neutralizing Antibody Levels Versus Peak Responses After Primary Vaccination (PR Newswire)
05.08.21	Novavax Announces COVID-19 Vaccine Booster Data Demonstrating Four-Fold Increase in Neutralizing Antibody Levels Versus Peak Responses After Primary Vaccination (PR Newswire)
05.08.21	Novavax Announces COVID-19 Vaccine Booster Data Demonstrating Four-Fold Increase in Neutralizing Antibody Levels Versus Peak Responses After Primary Vaccination (PR Newswire)
05.08.21	Novavax and Serum Institute of India Announce Submission to Regulatory Agencies in India, Indonesia, Philippines for Emergency Use Authorization of Novavax' Recombinant Nanoparticle COVID-19 Vaccine (PR Newswire)
05.08.21	Novavax and Serum Institute of India Announce Submission to Regulatory Agencies in India, Indonesia, Philippines for Emergency Use Authorization of Novavax' Recombinant Nanoparticle COVID-19 Vaccine (PR Newswire)
05.08.21	Novavax and Serum Institute of India Announce Submission to Regulatory Agencies in India, Indonesia, Philippines for Emergency Use Authorization of Novavax' Recombinant Nanoparticle COVID-19 Vaccine (PR Newswire)
05.08.21	Novavax und die Europäische Kommission schliessen einen Vorabkaufvertrag über bis zu 200 Millionen Dosen des Impfstoffs gegen COVID-19 ab (PR Newswire)
04.08.21	Novavax Says European Commission Finalizes Purchase Deal For Up To 200 Mln Doses Of COVID-19 Vaccine (RTTNews)
04.08.21	Novavax and European Commission Finalize Advance Purchase Agreement for up to 200 million doses of COVID-19 Vaccine (PR Newswire)
04.08.21	Novavax and European Commission Finalize Advance Purchase Agreement for up to 200 million doses of COVID-19 Vaccine (PR Newswire)
04.08.21	Novavax and European Commission Finalize Advance Purchase Agreement for up to 200 million doses of COVID-19 Vaccine (PR Newswire)
04.08.21	Novavax and European Commission Finalize Advance Purchase Agreement for up to 200 million doses of COVID-19 Vaccine (PR Newswire)
03.08.21	Ausblick: Novavax stellt Zahlen zum jüngsten Quartal vor (finanzen.net)
21.07.21	Erste Schätzungen: Novavax präsentiert das Zahlenwerk zum abgelaufenen Jahresviertel (finanzen.net)
06.07.21	Novavax to Host Conference Call to Discuss Second Quarter Financial Results and Operational Highlights on August 5, 2021 (PR Newswire)
30.06.21	Novavax Publishes Results of United Kingdom Phase 3 Clinical Trial in New England Journal of Medicine, Demonstrating High Levels of Efficacy of COVID-19 Vaccine (PR Newswire)
30.06.21	Novavax Publishes Results of United Kingdom Phase 3 Clinical Trial in New England Journal of Medicine, Demonstrating High Levels of Efficacy of COVID-19 Vaccine (PR Newswire)
17.06.21	MÄRKTE USA/Wall Street uneinheitlich - Technologiewerte gesucht (Dow Jones)
17.06.21	Novavax to Participate in Fireside Chat at SVB Leerink CybeRx Series: Vaccine Forum (PR Newswire)
17.06.21	MÄRKTE USA/Aussicht auf frühere Zinswende bremst Wall Street (Dow Jones)
17.06.21	Novavax to Participate in National Vaccine Advisory Committee Meeting (PR Newswire)
17.06.21	MÄRKTE USA/Aussicht auf frühere Zinswende dürfte erneut belasten (Dow Jones)
16.06.21	Le vaccin Novavax contre la COVID-19 démontre une efficacité globale de 90 % et une protection complète contre les formes modérées et graves de la maladie dans l'étude de phase 3 PREVENT-19 (PR Newswire)
15.06.21	Le vaccin de Novavax contre la COVID-19 démontre une efficacité globale de 90 % et une protection de 100 % contre les formes modérées et graves de la maladie durant l'essai de phase 3 PREVENT-19 (PR Newswire)
15.06.21	PREVENT-19-Phase-III-Studie: Der COVID-19-Impfstoff von Novavax zeigt eine Gesamtwirksamkeit von 90 % und einen 100 %igen Schutz vor mittelschweren und schweren Krankheitsverläufen (PR Newswire)
15.06.21	Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial (PR Newswire)
14.06.21	Novavax Reports Positive Results From Study Of Influenza, COVID-19 Vaccine Administered Together (RTTNews)
14.06.21	MÄRKTE USA/Uneinheitlich - Fed-Sitzung im Fokus (Dow Jones)
14.06.21	Novavax Announces Positive Results from First Study of Influenza Vaccine and COVID-19 Vaccine Candidate Administered Simultaneously (PR Newswire)
14.06.21	Novavax Announces Positive Results from First Study of Influenza Vaccine and COVID-19 Vaccine Candidate Administered Simultaneously (PR Newswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Novartis	92.75	0.89 %	K V
Nestle	76.36	0.69 %	K V
Swisscom	506.50	0.50 %	K V
Alcon	78.00	0.49 %	K V
Roche Hldg G	252.50	0.44 %	K V
CieFinRichemont	121.90	-0.37 %	K V
Sika	226.60	-0.87 %	K V
ABB	49.02	-1.05 %	K V
Lonza Grp	517.00	-2.64 %	K V
Logitech Intl	70.06	-2.67 %	K V

mehr

27.11.24		Schwacher Wochentag in New York: NASDAQ 100 verbucht letztendlich Abschläge
27.11.24		Schwacher Wochentag in New York: Dow Jones verliert am Mittwochmittag
27.11.24		Schwacher Wochentag in New York: NASDAQ 100 verbucht Verluste
27.11.24		Mittwochshandel in London: FTSE 100 legt zum Handelsende zu
27.11.24		Schwache Performance in Europa: Euro STOXX 50 gibt letztendlich nach
27.11.24		STOXX 50 aktuell: STOXX 50 zeigt sich zum Handelsende schwächer
27.11.24		Schwacher Handel: SLI zum Handelsende im Minus